Literature DB >> 22585001

Gynaecological cancer: OCEANS' three: the ovarian job.

M Teresa Villanueva.   

Abstract

Entities:  

Year:  2012        PMID： 22585001     DOI： 10.1038/nrclinonc.2012.84

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

Authors:  Susana Banerjee; Stan B Kaye
Journal:  Nat Rev Clin Oncol       Date:  2012-02-28       Impact factor: 66.675

2.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Carol Aghajanian; Stephanie V Blank; Barbara A Goff; Patricia L Judson; Michael G Teneriello; Amreen Husain; Mika A Sovak; Jing Yi; Lawrence R Nycum
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544
  2 in total
  1 in total

1.  Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs.

Authors:  Kellie S Rath; Georgia A McCann; David E Cohn; Brian K Rivera; Periannan Kuppusamy; Karuppaiyah Selvendiran
Journal:  J Ovarian Res       Date:  2013-05-11       Impact factor: 4.234
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.